• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Angina (Angina Pectoris) - Pipeline Review, Q3 2011 - Product Image

Angina (Angina Pectoris) - Pipeline Review, Q3 2011

  • ID: 1863288
  • July 2011
  • 69 pages
  • Global Markets Direct

Angina (Angina Pectoris) - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Angina (Angina Pectoris) - Pipeline Review, Q3 2011', provides an overview of the Angina (Angina Pectoris) therapeutic pipeline. This report provides information on the therapeutic development for Angina (Angina Pectoris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris). 'Angina (Angina Pectoris) - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Angina (Angina Pectoris).
- A review of the Angina (Angina Pectoris) products under development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) Overview
Therapeutics Development
An Overview of Pipeline Products for Angina (Angina Pectoris)
Angina (Angina Pectoris) Therapeutics under Development by Companies
Angina (Angina Pectoris) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Angina (Angina Pectoris) Therapeutics - Products under Development by Companies
Angina (Angina Pectoris) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Angina (Angina Pectoris) Therapeutics Development
Cardium Therapeutics, Inc.
Sanofi-Aventis
Merck & Co., Inc.
CardioVascular BioTherapeutics, Inc.
Ark Therapeutics Group plc
Bayer AG
Torrent Pharmaceuticals Limited
Hanall Pharmaceutical Co., Ltd.
Circ Pharma Limited
HUYA Bioscience International, LLC
Diakron Pharmaceuticals, Inc.
Lacer, S.A.
Viromed Co., Ltd.
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0974 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celivarone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Generx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-3005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capadenoson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T89 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL038 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sertraline + Omega-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fondaparinux - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bosentan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folic acid + Tetrahydrobiopterin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenosine A1 Agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endothelial Progenitor Cell CD 133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capsaicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F 15845 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IS5MN PM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bisoprolol PM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD34 + Adult Stem Cell Injection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBI-3000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBI-3000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRC-2XXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates
Angina (Angina Pectoris) Therapeutics - Discontinued Products
Angina (Angina Pectoris) - Featured News
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients
Mar 18, 2011: Cytokinetics Announces Fundamental Research In Field Of Cardiac Myosin Activation Published In Journal Science
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
Aug 06, 2010: The Medicines Company Receives One-Year Interim Patent Extension For Angiomax From USPTO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Angina (Angina Pectoris), Q3 2011
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Cardium Therapeutics, Inc., 2011
Sanofi-Aventis, 2011
Merck & Co., Inc., 2011
CardioVascular BioTherapeutics, Inc., 2011
Ark Therapeutics Group plc, 2011
Bayer AG, 2011
Torrent Pharmaceuticals Limited, 2011
Hanall Pharmaceutical Co., Ltd., 2011
Circ Pharma Limited, 2011
HUYA Bioscience International, LLC, 2011
Diakron Pharmaceuticals, Inc., 2011
Lacer, S.A., 2011
Viromed Co., Ltd., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Angina (Angina Pectoris), Q3 2011
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos